ImmunityBio, Inc. (IBRX)

The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing a...

ImmunityBio delivered strong 3Q25 results, with Anktiva driving 434% YoY product revenue growth and a narrowed operating loss. IBRX's cash position improved to $257.8 million, providing a 3-4 quarter ...

Bought 6,565,709 shares of ImmunityBio, an increase of $16.15 million in position value This new position ranks as the fund's 2nd-largest holding, representing 4.4% of AUM...

ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-...

CULVER CITY, Calif.--(BUSINESS WIRE)--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder canc...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30...

Chicago Partners Investment Group LLC purchased a new stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) in the second quarter, according to its most recent disclosure with the Securities and Exchang...

ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up...

Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves i...